Long-term analysis of ABI auditory performance in patients with neurofibromatosis type 2-related schwannomatosis.


Journal

Acta neurochirurgica
ISSN: 0942-0940
Titre abrégé: Acta Neurochir (Wien)
Pays: Austria
ID NLM: 0151000

Informations de publication

Date de publication:
02 Oct 2024
Historique:
received: 12 07 2024
accepted: 17 08 2024
medline: 2 10 2024
pubmed: 2 10 2024
entrez: 2 10 2024
Statut: epublish

Résumé

This retrospective monocentric study aimed to evaluate long-term auditory brainstem implant (ABI) function in patients with neurofibromatosis type 2, and to investigate the prognostic factors for ABI use. Between 1997 and 2022, 27 patients with at least five years of follow-up underwent implantation with 32 ABIs. At 1- and 5-years post-implantation and at last follow-up, ABIs were classified as used or non-used and the size of the ipsilateral tumor was recorded. For patients who used their ABIs, we assessed speech perception (disyllabic words, MBAA sentences) in quiet conditions with the ABI only, by lip-reading (LR), and with a combination of the two (ABI + LR). Hearing improvement was calculated as One year post-implantation, 74% patients were ABI-users and 66% of the ABIs were used. Two of these patients were non-users at five years, and another two at last follow-up (14 ± 5.2 years); 54% of the patients were ABI-users at last follow-up. ABIs are indicated in case of bilateral deafness with a non-functional cochlear nerve. Half the patients with ABIs used their implants and auditory performance remained stable over time, except in cases of ipsilateral tumor growth.

Identifiants

pubmed: 39356313
doi: 10.1007/s00701-024-06243-3
pii: 10.1007/s00701-024-06243-3
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

390

Informations de copyright

© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Références

Daoudi H, Lahlou G, Degos V, Sterkers O, Nguyen Y, Kalamarides M (2020) Improving facial nerve outcome and hearing preservation by different degrees of vestibular schwannoma resection guided by intraoperative facial nerve electromyography. Acta Neurochir (Wien) 162:1983–1993
doi: 10.1007/s00701-020-04397-4 pubmed: 32424567
Dornhoffer JR, Plitt AR, Lohse CM, Driscoll CLW, Neff BA, Saoji AA, Van Gompel JJ, Link MJ, Carlson ML (2024) Comparing Speech Recognition Outcomes Between Cochlear Implants and Auditory Brainstem Implants in Patients With NF2-Related Schwannomatosis. Otol Neurotol 45:29–35
pubmed: 37875011
Edgerton BJ, House WF, Hitselberger W (1982) Hearing by cochlear nucleus stimulation in humans. Ann Otol Rhinol Laryngol Suppl 91:117–124
pubmed: 6805391
Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R (1992) A clinical study of type 2 neurofibromatosis. Q J Med 84:603–618
pubmed: 1484939
Gadenstaetter AJ, Auinger AB, Gerlitz M, Riss D, Dahm V, Yildiz E, Roessler K, Matula C, Arnoldner C (2023) Functional Outcome After Simultaneous Vestibular Schwannoma Resection and Cochlear Implantation With Intraoperative Cochlear Nerve Monitoring. Otolaryngol Head Neck Surg 168:1502
doi: 10.1002/ohn.233 pubmed: 36856581
Grayeli AB, Kalamarides M, Bouccara D, Ambert-Dahan E, Sterkers O (2008) Auditory brainstem implant in neurofibromatosis type 2 and non-neurofibromatosis type 2 patients. Otol Neurotol 29:1140–1146
doi: 10.1097/MAO.0b013e31818b6238 pubmed: 18849886
Grenier B, Mosnier I, Ferrary E, Nguyen Y, Sterkers O, Kalamarides M, Lahlou G, Daoudi H (2024) Cochlear implantation in neurofibromatosis type 2-related schwannomatosis: long-term hearing outcomes. Otolaryngol Head Neck Surg 171:218
doi: 10.1002/ohn.702 pubmed: 38482961
Guex AA, Vachicouras N, Hight AE, Brown MC, Lee DJ, Lacour SP (2015) Conducting polymer electrodes for auditory brainstem implants. J Mater Chem B 3:5021–5027
doi: 10.1039/C5TB00099H pubmed: 26207184 pmcid: 4507441
Halliday D, Emmanouil B, Pretorius P, MacKeith S, Painter S, Tomkins H, Evans DG, Parry A (2017) Genetic Severity Score predicts clinical phenotype in NF2. J Med Genet 54:657–664
doi: 10.1136/jmedgenet-2017-104519 pubmed: 28848060
Iannacone FP, Visconti F, Zanoletti E (2023) How Cochlear Implant Rehabilitation Impacts the Therapeutic Strategy for Vestibular Schwannoma. Audiol Res 13:116–129
doi: 10.3390/audiolres13010012 pubmed: 36825950 pmcid: 9952590
Jia H, El Sayed MME, Smail M, Mosnier I, Wu H, Sterkers O, Kalamarides M, Bernardeschi D (2018) Neurofibromatosis type 2: Hearing preservation and rehabilitation. Neurochirurgie 64:348–354
doi: 10.1016/j.neuchi.2018.09.003 pubmed: 30314805
Jia H, Torres R, Nguyen Y, De Seta D, Ferrary E, Wu H, Sterkers O, Bernardeschi D, Mosnier I (2018) Intraoperative Conebeam CT for Assessment of Intracochlear Positioning of Electrode Arrays in Adult Recipients of Cochlear Implants. Am J Neuroradiol 39:768–774
doi: 10.3174/ajnr.A5567 pubmed: 29472297 pmcid: 7410755
Kuchta J (2007) Twenty-five years of auditory brainstem implants: perspectives. Acta Neurochir Suppl 97:443–449
doi: 10.1007/978-3-211-33081-4_51 pubmed: 17691334
Lenarz T, Moshrefi M, Matthies C, Frohne C, Lesinski-Schiedat A, Illg A, Rost U, Battmer RD, Samii M (2001) Auditory brainstem implant: part I. Auditory performance and its evolution over time. Otol Neurotol 22:823–833
doi: 10.1097/00129492-200111000-00019 pubmed: 11698803
Maini S, Cohen MA, Hollow R, Briggs R (2009) Update on long-term results with auditory brainstem implants in NF2 patients. Cochlear Implants Int 10(Suppl 1):33–37
doi: 10.1002/cii.383 pubmed: 19230037
Nakatomi H, Miyawaki S, Kin T, Saito N (2016) Hearing Restoration with Auditory Brainstem Implant. Neurol Med Chir (Tokyo) 56:597–604
doi: 10.2176/nmc.ra.2016-0080 pubmed: 27464470
Nevison B, Laszig R, Sollmann W-P et al (2002) Results from a European clinical investigation of the Nucleus multichannel auditory brainstem implant. Ear Hear 23:170–183
doi: 10.1097/00003446-200206000-00002 pubmed: 12072610
Noonan KY, Rock J, Barnard Z, Lekovic GP, Brackmann DE, Wilkinson EP (2021) Bilateral Auditory Brainstem Implants in Patients With Neurofibromatosis 2. Otolaryngol Head Neck Surg 165:339–343
doi: 10.1177/0194599820977420 pubmed: 33317418
Peng KA, Lorenz MB, Otto SR, Brackmann DE, Wilkinson EP (2018) Cochlear implantation and auditory brainstem implantation in neurofibromatosis type 2. Laryngoscope 128:2163–2169
doi: 10.1002/lary.27181 pubmed: 29573425
Peyre M, Bernardeschi D, Sterkers O, Kalamarides M (2018) Natural history of vestibular schwannomas and hearing loss in NF2 patients. Neurochirurgie 64:342–347
doi: 10.1016/j.neuchi.2015.03.012 pubmed: 26183546
Peyre M, Goutagny S, Bah A, Bernardeschi D, Larroque B, Sterkers O, Kalamarides M (2013) Conservative management of bilateral vestibular schwannomas in neurofibromatosis type 2 patients: hearing and tumor growth results. Neurosurgery 72:907–913; discussion 914; quiz 914
Plotkin SR, Messiaen L, Legius E et al (2022) Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genet Med 24:1967–1977
doi: 10.1016/j.gim.2022.05.007 pubmed: 35674741
Ramsden RT, Freeman SRM, Lloyd SKW et al (2016) Auditory Brainstem Implantation in Neurofibromatosis Type 2: Experience From the Manchester Programme. Otol Neurotol 37:1267–1274
doi: 10.1097/MAO.0000000000001166 pubmed: 27525707
Shi J, Lu D, Gu R, Sun H, Yu L, Pan R, Zhang Y (2021) Reliability and toxicity of bevacizumab for neurofibromatosis type 2-related vestibular schwannomas: A systematic review and meta-analysis. Am J Otolaryngol 42:103148
doi: 10.1016/j.amjoto.2021.103148 pubmed: 34214711
Siegbahn M, Lundin K, Olsson G-B, Stillesjö F, Kinnefors A, Rask-Andersen H, Nyberg G (2014) Auditory brainstem implants (ABIs)–20 years of clinical experience in Uppsala, Sweden. Acta Otolaryngol 134:1052–1061
doi: 10.3109/00016489.2014.909051 pubmed: 24881643
Taslimi S, Zuccato JA, Mansouri A, Hachem LD, Badhiwala J, Kuchta J, Chen J, Pirouzmand F (2019) Novel Statistical Analyses to Assess Hearing Outcomes After ABI Implantation in NF2 Patients: Systematic Review and Individualized Patient Data Analysis. World Neurosurg 128:e669–e682
doi: 10.1016/j.wneu.2019.04.232 pubmed: 31059859
Vincent C (2012) Auditory brainstem implants: how do they work? Anat Rec (Hoboken) 295:1981–1986
doi: 10.1002/ar.22588 pubmed: 23044901
Wong K, Kozin ED, Kanumuri VV, Vachicouras N, Miller J, Lacour S, Brown MC, Lee DJ (2019) Auditory Brainstem Implants: Recent Progress and Future Perspectives. Front Neurosci 13:10
doi: 10.3389/fnins.2019.00010 pubmed: 30760974 pmcid: 6361749

Auteurs

Hannah Daoudi (H)

ENT Department, Pitié-Salpêtrière, APHP, Sorbonne University, Paris, France. hannah.daoudi@aphp.fr.
Université Paris Cité, Institut Pasteur, AP-HP, InsermFondation Pour L'AuditionInstitut de L'Audition, Technologies and Gene Therapy for Deafness, IHU reConnect, 75012, Paris, France. hannah.daoudi@aphp.fr.
ENT Department, Rothschild, APHP, Sorbonne University, Paris, France. hannah.daoudi@aphp.fr.

Renato Torres (R)

ENT Department, Pitié-Salpêtrière, APHP, Sorbonne University, Paris, France.
Université Paris Cité, Institut Pasteur, AP-HP, InsermFondation Pour L'AuditionInstitut de L'Audition, Technologies and Gene Therapy for Deafness, IHU reConnect, 75012, Paris, France.

Isabelle Mosnier (I)

ENT Department, Pitié-Salpêtrière, APHP, Sorbonne University, Paris, France.
Université Paris Cité, Institut Pasteur, AP-HP, InsermFondation Pour L'AuditionInstitut de L'Audition, Technologies and Gene Therapy for Deafness, IHU reConnect, 75012, Paris, France.

Emmanuelle Ambert-Dahan (E)

ENT Department, Pitié-Salpêtrière, APHP, Sorbonne University, Paris, France.

Amélie Liagre-Cailles (A)

ENT Department, Pitié-Salpêtrière, APHP, Sorbonne University, Paris, France.

Mustapha Smail (M)

ENT Department, Pitié-Salpêtrière, APHP, Sorbonne University, Paris, France.

Yann Nguyen (Y)

ENT Department, Pitié-Salpêtrière, APHP, Sorbonne University, Paris, France.
Université Paris Cité, Institut Pasteur, AP-HP, InsermFondation Pour L'AuditionInstitut de L'Audition, Technologies and Gene Therapy for Deafness, IHU reConnect, 75012, Paris, France.

Evelyne Ferrary (E)

ENT Department, Pitié-Salpêtrière, APHP, Sorbonne University, Paris, France.
Université Paris Cité, Institut Pasteur, AP-HP, InsermFondation Pour L'AuditionInstitut de L'Audition, Technologies and Gene Therapy for Deafness, IHU reConnect, 75012, Paris, France.

Olivier Sterkers (O)

ENT Department, Pitié-Salpêtrière, APHP, Sorbonne University, Paris, France.

Ghizlène Lahlou (G)

ENT Department, Pitié-Salpêtrière, APHP, Sorbonne University, Paris, France.
Université Paris Cité, Institut Pasteur, AP-HP, InsermFondation Pour L'AuditionInstitut de L'Audition, Technologies and Gene Therapy for Deafness, IHU reConnect, 75012, Paris, France.

Michel Kalamarides (M)

Neurosurgery Department, Pitié-Salpêtrière, APHP, Sorbonne University, Paris, France.
Genetics and Development of Brain Tumors, CRICM Inserm CNRS, Paris Brain Institute, Paris, France.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH